Dianthus Therapeutics: Promising Developments and Market Potential Drive Buy Rating

Analyst Rami Katkhuda of LifeSci Capital maintained a Buy rating on Dianthus Therapeutics, retaining the price target of $45.00.

Rami Katkhuda has given his Buy rating due to a combination of factors surrounding Dianthus Therapeutics’ promising developments. The company is on the verge of releasing important data from its Phase II MaGic study, which evaluates the safety and efficacy of claseprubart in treating generalized myasthenia gravis (gMG). This study is significant as it will be the first to demonstrate the efficacy of an active C1s inhibitor in gMG, potentially marking a pivotal moment for the company. Although the study is not powered for statistical significance, expectations are set for improvements in key efficacy measures that align with existing approved treatments.
Katkhuda also highlights the potential of claseprubart to be a best-in-class treatment due to its convenient self-administration and lack of severe safety warnings, which differentiates it from other treatments. The commercial opportunity in the gMG market is substantial and growing, and the upcoming data readout, along with other internal and external catalysts expected over the next year, positions Dianthus Therapeutics favorably. These factors collectively underpin Katkhuda’s optimistic outlook and Buy rating for the stock.

In another report released on August 11, H.C. Wainwright also reiterated a Buy rating on the stock with a $40.00 price target.